PB 39, a gene dysregulated in prostate cancer, and uses thereof

Chemistry: molecular biology and microbiology – Measuring or testing process involving enzymes or... – Involving nucleic acid

Reexamination Certificate

Rate now

  [ 0.00 ] – not rated yet Voters 0   Comments 0

Details

C435S091100, C435S091200, C435S094000, 53, 53, 53, 53

Reexamination Certificate

active

09743825

ABSTRACT:
A novel gene, PB39, that is up-regulated, or over-expressed, in prostate cancer has been identified. The gene has been identified by means of its cDNA obtained by reverse transcription of the corresponding mRNA. Microdissection of prostate glands that had been surgically removed from prostate cancer patients revealed a novel up-regulated transcript in an aggressive prostate carcinoma. Differential analysis for the presence of this gene was carried out from the same glands by comparing transcription in microdissected normal prostatic epithelium versus that in microdissected invasive tumor. The transcript was over-expressed in 5 of 10 prostate carcinomas examined. A variant transcript was over-expressed in 4 of 4 prostate carcinomas, and was found in 1 of 4 normal samples. The invention provides a purified and isolated nucleic acid that includes the sequence of PB39 or its complement, the sequence of a variant of PB39 or its complement, and a primer or probe, that includes a sequence that is a fragment of these sequences. Additionally, the polypeptide encoded by these genes, an antibody to the polypeptide, and methods of detection of PB39 or its gene product are provided.

REFERENCES:
patent: 5330892 (1994-07-01), Vogelstein et al.
patent: 5380645 (1995-01-01), Vogelstein
patent: 5501983 (1996-03-01), Lilja et al.
patent: 5506106 (1996-04-01), Croce et al.
patent: 5543296 (1996-08-01), Sobol et al.
patent: 5552277 (1996-09-01), Nelson et al.
patent: 5567586 (1996-10-01), Croce
patent: 5569753 (1996-10-01), Wigler et al.
patent: 5571710 (1996-11-01), Barnett et al.
patent: 5582972 (1996-12-01), Lima et al.
patent: 5591582 (1997-01-01), Bos et al.
patent: 5605799 (1997-02-01), White et al.
patent: 5614372 (1997-03-01), Lilja et al.
patent: 5622829 (1997-04-01), King et al.
patent: 5648212 (1997-07-01), Albertson et al.
patent: 5650500 (1997-07-01), Raz et al.
patent: 5658730 (1997-08-01), McGill et al.
patent: 5674682 (1997-10-01), Croce et al.
patent: 5763202 (1998-06-01), Horoszewicz
patent: 5912143 (1999-06-01), Bandman et al.
patent: WO 098/10098 (1998-03-01), None
patent: WO 98/21328 (1998-05-01), None
Bowie et al (Science, 1990, 257: 1306-1310).
Burgess et al, (Journal of Cell Biology, 1990, 11: 2129-2138).
Lazar et al. Molecular and Cell Biology, 1988, 8: 1247-1252.
Tao. et al. The Journal of Immunology, 1989, 143(8): 2595-2601.
Gillies et al. Human Antibodies and Hybridomas, 1990, 1(1): 47-54.
Sambrook et al, eds, 1989, 2nd ed, Molecular Cloning, a laboratory manual, Cold Spring Harbor Laboratory Press, Cold Spring Harbor, p. 11.52.
Kibel, AS et al, 2000, J urol, 164(1): 192-6.
Zhau, HE, 1994, J Cell Biochem, Suppl 19: 208-216.
Cheung S T et al, 2002, Cancer Research, 62(16): 4711-21.
Ren, C et al, 1998, Cancer Res, 58(6): 1285-90.
Gingrich, JR et al, 1996, Cancer res, 56(18):4096-4102.
Boehringer Mannheim Biochemicals, 1994 Catalog, p. 93.
MPSRCH sequence search report, 2004, us-09-743-825-1.rng, pp. 4-6.
Genbank Sequence Database, Accession No: G22380, and MPSRCH search report, 2004, us-09-743-825-7.rge, p. 1-2, and us-09-743-825-10.rge, p. 1-2.
JP08154685-A, and MPSRCH search report, 2006, us-09-743825-7.rng, pp. 7-8.
US 6,509,163-B1, and MPSRCH search report, 2006, us-09-743825-8rng, p. 4.
US 6,849,399-B1, and MPSRCH search report, 2006, us-09-743825-10.rng, pp. 4.
Phyllis A. Wingo et al., “Cancer Statistics, 1995,” A Cancer Journal for Clinicians, vol. 45, No. 1, Jan./Feb. 1995, pp. 8-30.
Piotr Chomcsnynski et al., “Single-Step Method for RNA Isolation by Acid Guanidinium Thiocyanate-Phenol-Chloroform Extraction,” Analytical Biochemestry 162, pp. 156-159, 1987.
Michael R. Emmert-Buck et al., “Increased Gelatinase A(MMP-2)and Cathepsin B Activity in Invasive Tumor Regions of Human Colon Cancer Samples,” American Journal of Pathology, vol. 145, No. 6, pp. 1285-1290, Dec. 1994.
Zhengping Zhuang et al., “A Microdissection Technique for Archival DNA Analysis of Specific Cell Populations in Lesions <1 mm in Size,” American Journal of Pathology, vol. 146, No. 3, pp. 620-625, Mar. 1995.
Brad Stone et al., “Targeted RNA Fingerprinting: The Cloning of Differentially-Expressed cDMA Fragments Enriched for Members of the Zinc Finger Gene Family,” Nucleic Acids Research, vol. 22, No. 13, pp. 2612-2618, 1994.
Rodrigo F. Chuaqui et al., “Identification of a Novel Transcript Up-Regulated in a Clinically Aggressive Prostate Carcinoma,” Urology, vol. 50, No. 2, pp. 302-307, 1997.
Michael R. Emmert-Buck et al., “Laser Capture Microdissection,” Science, vol. 274, Nov. 8, 1996.
David G. Bostwick et al., “Molecular Biology of Prostatic Intraepithelial Neoplasia,” The Prostate, vol. 29, pp. 117-34, 1996.
Samuel C. Mok et al., “Molecular Cloning of Differentially Expressed Genes in Human Epithelial Ovarian Cancer,” Gynecological Oncology, vol. 52, pp. 247-252, 1994.
Olivier Kocher et al., “Identification of a Novel Gene, Selectively Up-Regulated in Hujman Carcinomas, Using the Differential Display Technique,” Clinical Cancer Research, vol. 1, pp. 1209-1215, Oct. 1995.
Mark A. Watson et al., “Isolation of Differentially Expressed Sequence Tags from Human Breast Cancer,” Cancer Research, vol. 54, pp. 4598-4602, Sep. 1, 1994.
Peng Liang et al., “Differential Display and Cloning of Messenger RNAs from Human Breast Cancer versus Mammary Epithelian Cells,” Cancer Research, vol. 52, pp. 6966-6968 (Dec. 15, 1992.
Cole et al., “cDNA Sequencing and Analysis of POV1 (PB39): a Novel Gene Up-regulated in Prostate Cancer”,Genomics, vol. 51, No. 2, Jul. 1998, pp. 282-287, XP002120985, p. 282, col. 1; Figures 1 and 2.
Wingo P. et al., “Cancer Statistics, 1995,”Cancer Journal for Clinicians, vol. 45: No. 1, pp. 8-30 (1995).
Epstein J. et al., “Prediction of Progression Following Radical Prostatectomy: a Multivariate Analysis of 721 Men with Long-Term Follow-up”,American Journal of Surgical Pathology, vol. 20, No. 1, pp. 286-292 (1996).
Kozak M., “Structural Features in Eukaryotic mRNAs That Modulate the Initiation of Translation,”The Journal of Biological Chemistry, vol. 266, No. 30, pp. 19867-19870 (1991).
Kawana et al., “Location of KAL1 on the Short Arm of Human Chromosome II and Frequency of Allelic Loss in Advanced Human Prostate Cancer,”The Prostate, vol. 32, No. 3, pp. 205-213 (1997).
Pinkel, D. et al., “Fluorescence In Situ Hybridization with Human Chromosome-specific Libraries: Detection of the Trisomy 21 and Translocations of Chromosome 4,”Proceedings of the National Academy of Sciences of the United States of America, vol. 85, No. 23, pp. 9138-9142 (1988).
Hirai, M. et al., “A Method of Simultaneous Detection of Fluorescent G-bands and In Situ Hybridization Signals,”Cytogenetics and Cell Genetics, vol. 66, No. 3, pp. 149-151 (1994).
Dong, J.T. et al., KAI1, a Metastasis Suppressor Gene for Prostate Cancer on Human Chromosome 11p11.2,Science, vol. 268, pp. 884-886 (1995).

LandOfFree

Say what you really think

Search LandOfFree.com for the USA inventors and patents. Rate them and share your experience with other people.

Rating

PB 39, a gene dysregulated in prostate cancer, and uses thereof does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with PB 39, a gene dysregulated in prostate cancer, and uses thereof, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and PB 39, a gene dysregulated in prostate cancer, and uses thereof will most certainly appreciate the feedback.

Rate now

     

Profile ID: LFUS-PAI-O-3827358

  Search
All data on this website is collected from public sources. Our data reflects the most accurate information available at the time of publication.